We are discussing with international partners criteria and the process for an update of the #COVID19Vaccines. 💉
Vaccination campaigns could take place primarily once a year and at the start of the winter❄️. #EMAPresser

🐦🔗: https://n.respublicae.eu/EMA_News/status/1625844608402849793

The assessment of #COVID19Vaccine HIPRA 💉 is progressing, and we hope to conclude it very soon. #EMAPresser

🐦🔗: https://n.respublicae.eu/EMA_News/status/1625844808404049920

We collaborate closely with @WHO to enable access to safe and effective vaccines in many countries around the 🌍. #UnitedInProtection #EMAPresser

🐦🔗: https://n.respublicae.eu/EMA_News/status/1625844973110235138

EMA is in contact with developers of mucosal #COVID19vaccines. We are ready to discuss emerging data from the vaccines that have already been deployed in India 🇮🇳 and China 🇨🇳. #EMAPresser

🐦🔗: https://n.respublicae.eu/EMA_News/status/1625844975073214472

We are evaluating an #RSV vaccine for older adults with a possible recommendation in the next months.
There is a need to better protect vulnerable groups against respiratory viruses 🦠 that might cause disease waves in winter. #EMAPresser

🐦🔗: https://n.respublicae.eu/EMA_News/status/1625845192136720385

❗️ #LongCovid is high on our agenda.

Current focus of many researchers is characterisation of the disease burden & clinical symptoms.

We are engaging with developers to discuss the design of clinical studies & what concrete measurable outcomes may look like.

#EMAPresser

🐦🔗: https://n.respublicae.eu/EMA_News/status/1625845560493178880

#RealWorldData on the #Mpox vaccine show that it is effective, especially after 2⃣ doses.

Discussions are ongoing with developers of other vaccines for Mpox and other viruses of the same type.

#EMAPresser

🐦🔗: https://n.respublicae.eu/EMA_News/status/1625845803758518273